These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25143359)

  • 21. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
    Troester MA; Sun X; Allott EH; Geradts J; Cohen SM; Tse CK; Kirk EL; Thorne LB; Mathews M; Li Y; Hu Z; Robinson WR; Hoadley KA; Olopade OI; Reeder-Hayes KE; Earp HS; Olshan AF; Carey LA; Perou CM
    J Natl Cancer Inst; 2018 Feb; 110(2):176-82. PubMed ID: 28859290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women.
    Stark A; Kapke A; Schultz D; Brown R; Linden M; Raju U
    Breast Cancer Res Treat; 2008 Feb; 107(3):405-14. PubMed ID: 17431759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
    Bauer K; Parise C; Caggiano V
    BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women.
    Marker KM; Zavala VA; Vidaurre T; Lott PC; Vásquez JN; Casavilca-Zambrano S; Calderón M; Abugattas JE; Gómez HL; Fuentes HA; Picoaga RL; Cotrina JM; Neciosup SP; Castañeda CA; Morante Z; Valencia F; Torres J; Echeverry M; Bohórquez ME; Polanco-Echeverry G; Estrada-Florez AP; Serrano-Gómez SJ; Carmona-Valencia JA; Alvarado-Cabrero I; Sanabria-Salas MC; Velez A; Donado J; Song S; Cherry D; Tamayo LI; Huntsman S; Hu D; Ruiz-Cordero R; Balassanian R; Ziv E; Zabaleta J; Carvajal-Carmona L; Fejerman L;
    Cancer Res; 2020 May; 80(9):1893-1901. PubMed ID: 32245796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
    JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
    Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in breast cancer subtypes with age and race/ethnicity.
    Parise CA; Bauer KR; Caggiano V
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):44-52. PubMed ID: 19800812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
    Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
    J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status.
    Cunningham JE; Montero AJ; Garrett-Mayer E; Berkel HJ; Ely B
    Cancer Causes Control; 2010 Mar; 21(3):399-409. PubMed ID: 20024610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States).
    Tarone RE; Chu KC
    Cancer Causes Control; 2002 Feb; 13(1):7-14. PubMed ID: 11899120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry.
    Telli ML; Chang ET; Kurian AW; Keegan TH; McClure LA; Lichtensztajn D; Ford JM; Gomez SL
    Breast Cancer Res Treat; 2011 Jun; 127(2):471-8. PubMed ID: 20957431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
    Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
    Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.
    Parise CA; Caggiano V
    Cancer Causes Control; 2019 May; 30(5):417-424. PubMed ID: 30879205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women.
    Ma H; Lu Y; Marchbanks PA; Folger SG; Strom BL; McDonald JA; Simon MS; Weiss LK; Malone KE; Burkman RT; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2013; 15(5):R90. PubMed ID: 24070170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.